BIOC — Biocept Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapValue Trap
- $12.96m
- -$2.61m
- $61.25m
- 33
- 77
- 37
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.47 | ||
| Price to Tang. Book | 0.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.26 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.76% | ||
| Return on Equity | -49.72% | ||
| Operating Margin | -32.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.07 | 3.25 | 5.53 | 27.46 | 61.25 | 41.1 | 7.25 | 80.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood, and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name of CNSide. In addition to CNSide, its current blood-based testing includes its Target Selector technologies, which enables detection of specific gene mutations, such as EGFR, KRAS or BRAF, in cell-free ctDNA from blood samples, as well as specific protein and gene alterations, such as HER2 amplification, in circulating tumor cells (CTCs) isolated from blood. Its multi-modality combination of a cell capture and analysis method used with a cell-free tumor DNA approach provides both high-sensitivity and specificity and is applicable to a range of diagnostic applications in patients with metastatic carcinoma. It provides blood-based liquid biopsy technology.
Directors
- Samuel Riccitelli CHM (62)
- Margaret Faye Wilson NEC (83)
- Michael Nall PRE (58)
- Timothy Kennedy CFO (63)
- Darrell Taylor SVP
- Michael Dugan SVP (59)
- Michael Terry SVP (66)
- Michael Brown CCO
- Antonio Paternostro VPR
- Gary Marchetti OTH
- Tom Nauman OTH
- Tim Schofield OTH
- David Hale DRC (72)
- Antonino Morales DRC
- Linda Rubinstein DRC (54)
- Marsha Chandler IND (76)
- Bruce Gerhardt IND (70)
- Ivor Royston IND (76)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- June 28th, 2013
- Public Since
- February 5th, 2014
- No. of Shareholders
- 11
- No. of Employees
- 174
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 17,058,770
- Address
- 9955 Mesa Rim Road, SAN DIEGO, 92121
- Web
- https://biocept.com/
- Phone
- +1 8583208200
- Contact
- Jody Cain
- Auditors
- Mayer Hoffman & McCann P.C.
Upcoming Events for BIOC
Q1 2023 Biocept Inc Earnings Release
Similar to BIOC
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
Akili
NASDAQ Capital Market
FAQ
What is the Biocept share price?
As of Today at 18:03 UTC, shares in Biocept are trading at $0.76. This share price information is delayed by 15 minutes.
How has the Biocept share price performed this year?
Shares in Biocept last closed at $0.76 and the price had moved by -80.57% over the past 365 days. In terms of relative price strength the Biocept share price has underperformed the S&P500 Index by -78.34% over the past year.
What are the analyst and broker recommendations for Biocept?
The overall consensus recommendation for Biocept is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Biocept dividend yield?
Biocept does not currently pay a dividend.
Does Biocept pay a dividend?
Biocept does not currently pay a dividend.
When does Biocept next pay dividends?
Biocept does not currently pay a dividend.
How do I buy Biocept shares?
To buy shares in Biocept you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biocept?
As of the previous close price of $0.76, shares in Biocept had a market capitalisation of $12.96m.
Where are Biocept shares listed?
Here are the trading details for Biocept:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BIOC
What kind of share is Biocept?
Based on an overall assessment of its quality, value and momentum Biocept is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biocept share price forecast for 2022?
The analyst consensus target price for shares in Biocept is $7.50. That is 886.97% above the last closing price of $0.76.
Analysts covering Biocept currently have a consensus Earnings Per Share (EPS) forecast of -$0.93 for the next financial year.
What is the trend in the Biocept share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocept. Over the past six months, its share price has underperformed the S&P500 Index by -45.45%.
As of the last closing price of $0.76, shares in Biocept were trading -41.07% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biocept PE Ratio?
The Biocept PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biocept?
Biocept's management team is headed by:
- Samuel Riccitelli - CHM
- Margaret Faye Wilson - NEC
- Michael Nall - PRE
- Timothy Kennedy - CFO
- Darrell Taylor - SVP
- Michael Dugan - SVP
- Michael Terry - SVP
- Michael Brown - CCO
- Antonio Paternostro - VPR
- Gary Marchetti - OTH
- Tom Nauman - OTH
- Tim Schofield - OTH
- David Hale - DRC
- Antonino Morales - DRC
- Linda Rubinstein - DRC
- Marsha Chandler - IND
- Bruce Gerhardt - IND
- Ivor Royston - IND